Literature DB >> 2163098

Absence of circulating antineutrophil cytoplasm antibodies (ANCA) in severe vasculitis associated with rheumatoid arthritis.

L Nässberger1, A G Sjöholm, G Sturfelt.   

Abstract

Sixteen patients with classical rheumatoid arthritis (RA) complicated by severe vasculitis were studied and compared with a matched control group of 17 RA patients without vasculitis. A control group of 24 patients with unrelated disease was also included. Neither antineutrophil cytoplasmic antibodies (C-ANCA) nor anti-myeloperoxidase (anti-MPO) were found. Granulocyte specific antinuclear antibodies ("GS-ANA") were found in a higher frequency in the vasculitis group (75%) than in the RA control group (41%), but the difference was not statistically significant. No patient in the control group without RA had "GS-ANA".

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2163098     DOI: 10.3109/03009749009095042

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  4 in total

Review 1.  Systemic lupus erythematosus: RNA-protein autoantigens, models of disease heterogeneity, and theories of etiology.

Authors:  J B Harley; R H Scofield
Journal:  J Clin Immunol       Date:  1991-11       Impact factor: 8.317

2.  Antineutrophil cytoplasmic antibodies in Bulgarian patients with rheumatoid arthritis: characterization and clinical associations.

Authors:  Irena Manolova; Maria Dantcheva
Journal:  Rheumatol Int       Date:  2004-11-11       Impact factor: 2.631

3.  Antineutrophil cytoplasmic antibodies (ANCA) in rheumatoid arthritis: a prospective study.

Authors:  E Röther; T Schochat; H H Peter
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

4.  Anti-myeloperoxidase antibodies in patients with rheumatoid arthritis: prevalence, clinical correlates, and IgG subclass.

Authors:  G Cambridge; M Williams; B Leaker; M Corbett; C R Smith
Journal:  Ann Rheum Dis       Date:  1994-01       Impact factor: 19.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.